Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety and Efficacy of PRA-216 in Participants With Moderate to Severe Atopic Dermatitis

NCT07810777 is registered in ClinicalTrials.gov with Prana Therapies Inc as lead sponsor.

NCT NCT07810777
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07810777 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety and Efficacy of PRA-216 in Participants With Moderate to Severe Atopic Dermatitis
Lead sponsor
Prana Therapies Inc
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
October 1, 2027
Enrollment
39 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis (ad)